Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size

NCT01882179 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

61

Enrollment

OTHER

Sponsor class

Conditions

ST-elevation Myocardial Infarction

Interventions

DRUG: Mineralocorticoid receptor antagonist potassium-canrenoate
DRUG: placebo

Sponsor

University College, London

Collaborators

[object Object]